CELU - Celularity inks partnership with Imugene in solid tumors

Imugene (OTCPK:IUGNF) and Celularity (NASDAQ:CELU) have entered into a research collaboration to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the treatment of solid tumors. “In preclinical studies Celularity’s cellular therapies have shown the ability to overcome limitations that have hindered other approaches, including increased proliferation and persistence in vivo, resistance to T-cell exhaustion and low immunogenicity, which allows for repeated dosing," said Leslie Chong, Managing Director & Chief Executive Officer of Imugene. Nonclinical in vitro and in vivo combination studies to commence in 2021.

For further details see:

Celularity inks partnership with Imugene in solid tumors